Citadel Advisors’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $552K | Sell |
17,400
-600
| -3% | -$16.4K | ﹤0.01% | 9058 |
|
|
2025
Q4 | $489K | Sell |
18,000
-19,200
| -52% | -$506K | ﹤0.01% | 9074 |
|
|
2025
Q3 | $962K | Buy |
37,200
+4,000
| +12% | +$92.7K | ﹤0.01% | 7614 |
|
|
2025
Q2 | $676K | Sell |
33,200
-33,900
| -51% | -$660K | ﹤0.01% | 7923 |
|
|
2025
Q1 | $1.22M | Buy |
67,100
+40,300
| +150% | +$900K | ﹤0.01% | 6523 |
|
|
2024
Q4 | $677K | Sell |
26,800
-19,700
| -42% | -$535K | ﹤0.01% | 7898 |
|
|
2024
Q3 | $1.58M | Buy |
46,500
+25,200
| +118% | +$960K | ﹤0.01% | 5952 |
|
|
2024
Q2 | $788K | Sell |
21,300
-10,000
| -32% | -$377K | ﹤0.01% | 7075 |
|
|
2024
Q1 | $1.31M | Sell |
31,300
-13,300
| -30% | -$546K | ﹤0.01% | 6374 |
|
|
2023
Q4 | $1.77M | Buy |
44,600
+19,400
| +77% | +$571K | ﹤0.01% | 5589 |
|
|
2023
Q3 | $694K | Sell |
25,200
-1,600
| -6% | -$50.2K | ﹤0.01% | 7361 |
|
|
2023
Q2 | $909K | Buy |
26,800
+13,900
| +108% | +$468K | ﹤0.01% | 6655 |
|
|
2023
Q1 | $464K | Sell |
12,900
-12,300
| -49% | -$531K | ﹤0.01% | 8471 |
|
|
2022
Q4 | $1.12M | Buy |
25,200
+8,500
| +51% | +$303K | ﹤0.01% | 6586 |
|
|
2022
Q3 | $469K | Sell |
16,700
-207,500
| -93% | -$6.36M | ﹤0.01% | 8596 |
|
|
2022
Q2 | $6.04M | Buy |
224,200
+125,700
| +128% | +$3.65M | ﹤0.01% | 3459 |
|
|
2022
Q1 | $3.35M | Sell |
98,500
-25,500
| -21% | -$815K | ﹤0.01% | 4955 |
|
|
2021
Q4 | $4.79M | Sell |
124,000
-120,000
| -49% | -$5.23M | ﹤0.01% | 4360 |
|
|
2021
Q3 | $13.2M | Sell |
244,000
-16,500
| -6% | -$774K | ﹤0.01% | 2607 |
|
|
2021
Q2 | $8.71M | Buy |
260,500
+78,700
| +43% | +$2.16M | ﹤0.01% | 3316 |
|
|
2021
Q1 | $3.75M | Sell |
181,800
-48,100
| -21% | -$1.1M | ﹤0.01% | 4919 |
|
|
2020
Q4 | $4.03M | Buy |
229,900
+94,200
| +69% | +$1.7M | ﹤0.01% | 4052 |
|
|
2020
Q3 | $2.01M | Buy |
135,700
+98,100
| +261% | +$1.15M | ﹤0.01% | 4699 |
|
|
2020
Q2 | $489K | Buy |
+37,600
| New | +$167K | ﹤0.01% | 7112 |
|
|
2020
Q1 | – | Sell |
-13,000
| Closed | -$29K | – | 9632 |
|
|
2019
Q4 | $29K | Buy |
+13,000
| New | +$30.2K | ﹤0.01% | 8874 |
|
|
2018
Q4 | – | Sell |
-1,860
| Closed | -$13K | – | 9154 |
|
|
2018
Q3 | $13K | Sell |
1,860
-2,187
| -54% | -$15.3K | ﹤0.01% | 9083 |
|
|
2018
Q2 | $31K | Buy |
4,047
+94
| +2% | +$1.26K | ﹤0.01% | 8554 |
|
|
2018
Q1 | $138K | Sell |
3,953
-2,787
| -41% | -$108K | ﹤0.01% | 7588 |
|
|
2017
Q4 | $287K | Sell |
6,740
-13
| -0.2% | -$557 | ﹤0.01% | 6535 |
|
|
2017
Q3 | $290K | Sell |
6,753
-194
| -3% | -$7.27K | ﹤0.01% | 6120 |
|
|
2017
Q2 | $257K | Buy |
6,947
+954
| +16% | +$42.2K | ﹤0.01% | 6162 |
|
|
2017
Q1 | $325K | Sell |
5,993
-674
| -10% | -$35.1K | ﹤0.01% | 5770 |
|
|
2016
Q4 | $354K | Sell |
6,667
-613
| -8% | -$34.9K | ﹤0.01% | 5436 |
|
|
2016
Q3 | $441K | Sell |
7,280
-2,780
| -28% | -$173K | ﹤0.01% | 5046 |
|
|
2016
Q2 | $662K | Sell |
10,060
-4,107
| -29% | -$261K | ﹤0.01% | 4116 |
|
|
2016
Q1 | $803K | Buy |
14,167
+7,680
| +118% | +$864K | ﹤0.01% | 3746 |
|
|
2015
Q4 | $1.53M | Sell |
6,487
-893
| -12% | -$195K | ﹤0.01% | 3055 |
|
|
2015
Q3 | $1.17M | Buy |
7,380
+2,200
| +42% | +$623K | ﹤0.01% | 3616 |
|
|
2015
Q2 | $1.96M | Sell |
5,180
-4,640
| -47% | -$1.84M | ﹤0.01% | 3078 |
|
|
2015
Q1 | $4.11M | Buy |
9,820
+2,040
| +26% | +$730K | ﹤0.01% | 2243 |
|
|
2014
Q4 | $2.13M | Buy |
7,780
+187
| +2% | +$46.5K | ﹤0.01% | 2843 |
|
|
2014
Q3 | $1.48M | Buy |
7,593
+3,060
| +68% | +$667K | ﹤0.01% | 3223 |
|
|
2014
Q2 | $1.11M | Sell |
4,533
-1,960
| -30% | -$443K | ﹤0.01% | 3369 |
|
|
2014
Q1 | $1.72M | Buy |
6,493
+913
| +16% | +$350K | ﹤0.01% | 2815 |
|
|
2013
Q4 | $2.03M | Buy |
5,580
+1,120
| +25% | +$431K | ﹤0.01% | 2539 |
|
|
2013
Q3 | $2.37M | Buy |
4,460
+2,613
| +141% | +$896K | ﹤0.01% | 2252 |
|
|
2013
Q2 | $432K | Buy |
+1,847
| New | +$364K | ﹤0.01% | 3963 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Citadel Advisors's CLDX Position: Q1 2026 in Review
Citadel Advisors increased its Celldex Therapeutics (CLDX) stake by 264% in Q1 2026, buying an estimated $3.97M and bringing the position to 200,612 shares worth $6.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3953.
Citadel Advisors first reported a position in CLDX in Q2 2013 and has held it in 49 quarters since. The position peaked at $48.1M in Q1 2023. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Citadel Advisors held 200,612 shares of Celldex Therapeutics worth $6.36M as of Q1 2026.
- Citadel Advisors bought 145,511 Celldex Therapeutics shares in Q1 2026, an estimated $3.97M.
- Celldex Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3953 holding.
- Citadel Advisors first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 49 quarters since.
- Citadel Advisors's Celldex Therapeutics position peaked at $48.1M in Q1 2023.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.